FR2506158B1 - Medicament a base d'une association d'un inhibiteur de l'aromatase et d'un anti-androgene, utilisable pour le traitement et la prevention de l'hyperplasie de la prostate - Google Patents

Medicament a base d'une association d'un inhibiteur de l'aromatase et d'un anti-androgene, utilisable pour le traitement et la prevention de l'hyperplasie de la prostate

Info

Publication number
FR2506158B1
FR2506158B1 FR8120022A FR8120022A FR2506158B1 FR 2506158 B1 FR2506158 B1 FR 2506158B1 FR 8120022 A FR8120022 A FR 8120022A FR 8120022 A FR8120022 A FR 8120022A FR 2506158 B1 FR2506158 B1 FR 2506158B1
Authority
FR
France
Prior art keywords
useful
treatment
combination
androgen
prevention
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
FR8120022A
Other languages
English (en)
French (fr)
Other versions
FR2506158A1 (fr
Inventor
Hans-Udo Schweikert
Ulf Tunn
Theodor Senge
Friedmund Neumann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharma AG
Original Assignee
Schering AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering AG filed Critical Schering AG
Publication of FR2506158A1 publication Critical patent/FR2506158A1/fr
Application granted granted Critical
Publication of FR2506158B1 publication Critical patent/FR2506158B1/fr
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
FR8120022A 1981-05-22 1981-10-26 Medicament a base d'une association d'un inhibiteur de l'aromatase et d'un anti-androgene, utilisable pour le traitement et la prevention de l'hyperplasie de la prostate Expired FR2506158B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19813121152 DE3121152A1 (de) 1981-05-22 1981-05-22 "verwendung der kombination eines aromatase-hemmers mit einem antiandrogen zur prophylaxe und therapie der prostatahyperplasie"

Publications (2)

Publication Number Publication Date
FR2506158A1 FR2506158A1 (fr) 1982-11-26
FR2506158B1 true FR2506158B1 (fr) 1986-05-09

Family

ID=6133382

Family Applications (1)

Application Number Title Priority Date Filing Date
FR8120022A Expired FR2506158B1 (fr) 1981-05-22 1981-10-26 Medicament a base d'une association d'un inhibiteur de l'aromatase et d'un anti-androgene, utilisable pour le traitement et la prevention de l'hyperplasie de la prostate

Country Status (15)

Country Link
US (1) US4598072A (enExample)
JP (1) JPS57193412A (enExample)
AU (1) AU563785B2 (enExample)
BE (1) BE890522A (enExample)
CA (1) CA1186998A (enExample)
CH (1) CH648211A5 (enExample)
DE (1) DE3121152A1 (enExample)
DK (1) DK354881A (enExample)
FR (1) FR2506158B1 (enExample)
GB (1) GB2102287B (enExample)
IT (1) IT1139175B (enExample)
LU (1) LU83545A1 (enExample)
NL (1) NL8103875A (enExample)
SE (1) SE463074B (enExample)
ZA (1) ZA823501B (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3607651A1 (de) * 1986-03-06 1987-09-10 Schering Ag Kombination von aromatasehemmer und testosteron-5(alpha)-reduktase-hemmer
US4895715A (en) * 1988-04-14 1990-01-23 Schering Corporation Method of treating gynecomastia
US5372996A (en) * 1989-03-10 1994-12-13 Endorecherche, Inc. Method of treatment of androgen-related diseases
US5595985A (en) * 1989-03-10 1997-01-21 Endorecherche Inc. Combination therapy for prophylaxis and/or treatment of benign prostatic hyperplasia
US5364847A (en) * 1989-03-10 1994-11-15 Endorecherche Inhibitors of sex steroid biosynthesis and methods for their production and use
EP0480950B1 (en) * 1989-07-07 1999-03-24 Endorecherche Inc. Combination therapy for prophylaxis and/or treatment of benign prostatic hyperplasia
AU5851690A (en) * 1989-07-07 1991-02-06 Endorecherche Inc. Method of treatment of androgen-related diseases
DE4001060A1 (de) * 1990-01-16 1991-07-18 Kanoldt Arzneimittel Gmbh Verwendung einer ungesaettigten fettsaeure oder ihrer derivate in der human- und veterinaermedizin und zur herstellung einer arzneimittelzubereitung
WO1993023053A1 (en) * 1992-05-21 1993-11-25 Endorecherche Inc. INHIBITORS OF TESTOSTERONE 5α-REDUCTASE ACTIVITY
GB2278054A (en) * 1993-05-18 1994-11-23 Zeneca Ltd Compounds for the treatment of urinary incontinence
US6541463B1 (en) * 1998-03-11 2003-04-01 Endorecherche, Inc. Inhibitors of type 5 and type 3 17β-hydroxysteroid dehydrogenase and methods for their use
DE19825591A1 (de) * 1998-06-09 1999-12-23 Jenapharm Gmbh Pharmazeutische Kombinationen zum Ausgleich eines Testosteron-Defizits beim Mann mit gleichzeitigem Schutz der Prostata
GB9930839D0 (en) * 1999-12-30 2000-02-16 Pharmacia & Upjohn Spa Process for treating gynecomastia
GB0012293D0 (en) * 2000-05-23 2000-07-12 Astrazeneca Ab Pharmaceutical combination
EP1299094A2 (en) * 2000-06-28 2003-04-09 Bristol-Myers Squibb Company Selective androgen receptor modulators and methods for their identification, design and use
US20040077605A1 (en) * 2001-06-20 2004-04-22 Salvati Mark E. Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
US7001911B2 (en) 2000-06-28 2006-02-21 Bristol-Myers Squibb Company Fused cyclic modulators of nuclear hormone receptor function
WO2002002112A1 (en) * 2000-07-05 2002-01-10 Astrazeneca Ab Pharmaceutical combination of an anti-androgen and anastrozole for providing an antiandrogenic effect and aromatase inhibition
WO2002002113A1 (en) * 2000-07-05 2002-01-10 Astrazeneca Ab Pharmaceutical combination of an anti-androgen and letrozole for providing an anit-androgenic effect and aromatase inhibition
GB0016426D0 (en) * 2000-07-05 2000-08-23 Astrazeneca Ab Pharmaceutical combination
US6953679B2 (en) 2000-09-19 2005-10-11 Bristol-Myers Squibb Company Method for the preparation of fused heterocyclic succinimide compounds and analogs thereof
EP1854798A3 (en) * 2000-09-19 2007-11-28 Bristol-Myers Squibb Company Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
US20040087548A1 (en) 2001-02-27 2004-05-06 Salvati Mark E. Fused cyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
US6607755B2 (en) * 2001-06-21 2003-08-19 Michael Donald Farley Anti-aromatase pharmaceutical composition for controlling testosterone/estrone ratios
SE0103839D0 (sv) * 2001-11-16 2001-11-16 Astrazeneca Ab Pharmaceutical formulation & product
EP1467979B1 (en) * 2001-12-19 2008-08-13 Bristol-Myers Squibb Company Fused heterocyclic compounds and analogs thereof modulators of nuclear hormone receptor function
EP1738752A1 (en) 2002-12-27 2007-01-03 Schering Aktiengesellschaft Pharmaceutical combinations comprising cis-retine acid
PL2500062T3 (pl) * 2007-11-13 2015-12-31 Curadis Gmbh Steroidy C-19 do określonych zastosowań terapeutycznych
JP2012515184A (ja) * 2009-01-14 2012-07-05 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 大腸がんの治療方法
US10632087B2 (en) 2012-02-06 2020-04-28 Innovative Med Concepts, LLC. Famciclovir and meloxicam combination therapy for functional somatic syndromes
EP2762135A1 (en) * 2013-02-04 2014-08-06 Sanofi Methods for reducing the risk of an adverse teriflunomide and rosuvastatin interaction in multiple sclerosis patients
JP2017515800A (ja) * 2014-04-08 2017-06-15 ザ・メソジスト・ホスピタル ｉＮＯＳ阻害組成物および乳がん治療薬としてのその使用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3423507A (en) * 1966-02-25 1969-01-21 Schering Corp Method of treating benign prostratic hypertrophy
US3449494A (en) * 1966-09-29 1969-06-10 Squibb & Sons Inc Anti-inflammatory compositions containing a corticoidal steroid and a testololactone
US4055641A (en) * 1976-05-10 1977-10-25 Richardson-Merrell Inc. Method of treating benign prostatic hypertrophy
DE2817157A1 (de) * 1978-04-17 1979-10-25 Schering Ag Verwendung von antioestrogenen und antigonadotrop wirkenden antiandrogenen zur prophylaxe und therapie der prostatahyperplasie
US4235893A (en) * 1978-05-08 1980-11-25 Brodie Angela M Ester derivatives of 4-hydroxy-4-androstene-3,17-dione and a method for inhibiting estrogen biosynthesis
DE3362176D1 (en) * 1982-07-14 1986-03-27 Akzo Nv Novel 19-thio-androstane derivatives

Also Published As

Publication number Publication date
DE3121152C2 (enExample) 1991-02-07
ZA823501B (en) 1983-03-30
JPH0150207B2 (enExample) 1989-10-27
CA1186998A (en) 1985-05-14
JPS57193412A (en) 1982-11-27
BE890522A (fr) 1982-03-29
DK354881A (da) 1982-11-23
SE8104624L (sv) 1982-11-23
NL8103875A (nl) 1982-12-16
IT8123988A0 (it) 1981-09-16
SE463074B (sv) 1990-10-08
IT1139175B (it) 1986-09-24
AU563785B2 (en) 1987-07-23
CH648211A5 (de) 1985-03-15
US4598072A (en) 1986-07-01
FR2506158A1 (fr) 1982-11-26
DE3121152A1 (de) 1982-12-09
GB2102287B (en) 1985-02-27
LU83545A1 (de) 1981-12-01
AU8407582A (en) 1982-11-25
GB2102287A (en) 1983-02-02

Similar Documents

Publication Publication Date Title
FR2506158B1 (fr) Medicament a base d'une association d'un inhibiteur de l'aromatase et d'un anti-androgene, utilisable pour le traitement et la prevention de l'hyperplasie de la prostate
IT8026551A0 (it) Trattamenti e procedimento per inibire la corrosione di metalli.
DE122006000010I2 (de) Benzocyclobutyl- oder Indanyl-Alkyl-Amino-Alkyl substituierte 3-Benzazepin-2-ones, verwendbar in derBehandlung von kardiovaskularen Krankheiten
ZA871860B (en) Transglutaminase inhibitors
KR930701175A (ko) 인체 전립선 아데노카르시노마의 치료방법
DE3576328D1 (de) Behandlung feuerfester gegenstaende.
IT1168028B (it) Impiego di inibitori dell'aromatasi per la profilassi e la terapia della iperplasia della prostata
FI820115L (fi) Tetrahydronaftalen- och indanfoereningar
FR2556348B1 (fr) Retinoides, leur preparation et leurs utilisations therapeutiques, notamment pour le traitement des neoplasies, de l'acne et du psoriasis
DE3583258D1 (de) Schwimmbadwasserbehandlung.
GR76280B (enExample)
ES8101624A1 (es) Un procedimiento para la preparacion de espiroketalinas con propiedades anti-inflamatorias.
IT8421342A0 (it) Composizioni e composti per il trattamento dell'adenoma prostatico.
FI823817A7 (fi) Nitroimidatsoliyhdisteitä ja näppyjen hoidossa käyttökelpoisia seoksia.
US4439442B1 (enExample)
EP0213072A3 (en) Treatment of chronic imflammatory disease
GB1511196A (en) Creatinine pyrolidonecarboxylate
FR2517203B1 (fr) Composition pour le traitement de l'acne
BE892339A (fr) Agents pour le traitement d'affections cardiaques coronariennes
IT1090358B (it) Procedimento per il trattamento di pezzi di lavoro d'acciaio per impedirne la corrosione
IT1237326B (it) Tienil e benzotienil-terz.-butilamminofenossipropanoli per il trattamento di affezioni cardiovascolari
SU1405143A1 (ru) Способ лечения острых нарушений мозгового кровообращения
JPS5427518A (en) Treatment of ester
IT8324208A0 (it) Procedimento per la riduzione del contenuto di ferro dei bagni di fosfatazione.
IT8168143A0 (it) Composto per il trattamento e la prevenzione della diarrea in animali

Legal Events

Date Code Title Description
ST Notification of lapse